Skip to main content
Home / International Journal of Oncology, Volume 42, Number 2

Ephrin-A1 mRNA is associated with poor prognosis of colorectal cancer

Buy Article:

$42.00 + tax (Refund Policy)

We previously studied hypoxic tumor cells from hepatic metastases of colorectal cancer (CRC) and determined several potential prognostic factors, including expression of ephrin-A1 (EFNA1), which was highly induced by hypoxia. Here, we further evaluated the prognostic impact of EFNA1 expression. Samples from a total of 366 CRC patients from 11 institutes were analyzed by either microarray (n=220) or quantitative reverse-transcriptase polymerase chain reaction (n=146). EFNA1 was an independent prognostic factor for CRC (p<0.05). In vitro assays revealed that loss of EFNA1 following siRNA treatment was associated with reduced proliferative activity and decreased invasion and migration of CRC cell lines. EFNA1 expression is a useful marker for predicting high risk of relapse and cancer-related death in patients who have undergone curative resection for CRC.

Document Type: Research Article

Affiliations: 1: Department of Surgery, Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan 2: Department of Surgery, Kinki Central Hospital, Hyogo, Japan 3: Department of Surgery, Suita Municipal Hospital, Japan 4: Department of Surgery, Sakai City Hospital, Japan 5: Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan 6: Department of Surgery, NTT West Osaka Hospital, Osaka, Japan 7: Department of Surgery, Minoh City Hospital, Osaka, Japan 8: Department of Surgery, Kansai Rosai Hospital, Hyogo, Japan 9: Department of Surgery, National Hospital Organization, Osaka National Hospital, Osaka, Japan 10: Department of Molecular and Cellular Biology, Division of Molecular and Surgical Oncology, Kyushu University, Medical Institute of Bioregulation, Ohita, Japan

Publication date: 01 January 2013

More about this publication?
  • The International Journal of Oncology provides an international forum for the publication of the latest, cutting-edge research in the broad area of oncology and cancer treatment. The journal accepts original high quality works and reviews on all aspects of oncology research including carcinogenesis, metastasis, epidemiology, chemotherapy and viral oncology. Through fair and efficient peer review, the journal is dedicated to publishing top tier research in the field, offering authors rapid publication as well as high standards of copy-editing and production. The International Journal of Oncology is published on a monthly basis in both print and early online.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Information for Advertisers
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites

Share Content

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content